Insulin pump coverage criteria
This article was originally published in The Gray Sheet
Executive Summary
Review of Medtronic MiniMed's April 1 request that CMS remove the C-peptide testing requirement from insulin pump national coverage criteria will be complete by Oct. 1. The American Association of Clinical Endocrinologists and other opinion leaders plan to send letters supporting the change. CMS maintains that C-peptide level assesses "residual beta-cell function by measuring insulin secretory ability and ensuring appropriateness of the infusion pump"...